A Phase II Study of Cisplatin in Patients with Biliary Tract Carcinoma

Authors:
  • HIHiroshi Ishii
    Hiroshi Ishii
  • HNHaruhiko Nose
    Haruhiko Nose
  • MYMasayoshi Yoshimori
    Masayoshi Yoshimori
  • TOTakuji Okusaka
    Takuji Okusaka
  • KAKazunori Aoki
    Kazunori Aoki
  • MIMasahiko Iwasaki
    Masahiko Iwasaki
  • JFJunji Furuse
    Junji Furuse
  • MYMasahiro Yoshino
    Masahiro Yoshino

Abstract
A phase II study of cisplatin was performed in 13 previously untreated patients with unresectable biliary tract carcinoma. The drug was given intravenously at a dose of 80 mg/m2/day once every 4 weeks. Of 13 patients evaluated, 1 showed partial response lasting 3 months, while no patient showed complete response. Of 9 patients, whose serum level of carcinoembryonic antigen (CEA) was high (≥10 ng/ml) before treatment, 4 showed ≥50% reduction in serum CEA level after treatment. The current study indicates that cisplatin does not have significant antitumor activity against biliary tract carcinoma.